Elsulfavirine

Add links
Source: Wikipedia, the free encyclopedia.
Elsulfavirine
Clinical data
Trade namesElpida
Other namesVM 1500; elpivirine
ATC code
  • None
Legal status
Legal status
  • Rx-only in Russia
Identifiers
  • N-[4-[[2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-chlorophenyl]sulfonylpropanamide
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC24H17BrCl2FN3O5S
Molar mass629.28 g·mol−1
  • InChI=1S/C24H17BrCl2FN3O5S/c1-2-21(32)31-37(34,35)17-4-6-20(19(27)11-17)30-22(33)9-14-3-5-18(25)24(23(14)28)36-16-8-13(12-29)7-15(26)10-16/h3-8,10-11H,2,9H2,1H3,(H,30,33)(H,31,32)
  • Key:ULTDEARCBRNRGR-UHFFFAOYSA-N

Elsulfavirine (trade name Elpida; also known as VM 1500) is drug used to treat

non-nucleoside reverse transcriptase inhibitor (NNRTI).[1][2][3] Elsulfavirine is a prodrug which is metabolized to the active antiviral agent deselsulfavirine (also known as VM 1500A).[4] It was developed by the Russian company Viriom.[5]

In June 2017, elsulfavirine was approved for use in Russia as an oral formulation for the treatment of HIV-1 infections in combination with other antiretroviral drugs.

tenofovir.[7]

Long-acting injectable formulations of eslulfavarinin and deselsulfavarine are under investigation.[8][9]

In addition, Roche is investigating the use of elsulfavirin for the treatment of COVID-19 and it is currently in Phase II clinical trials for this possible indication.[5]

References

  1. S2CID 203439476
    .
  2. PMID 29737220
    .
  3. S2CID 203439476
    .
  4. ^
    S2CID 25316512
    .
  5. ^ a b "Elsulfavirine - Viriom". AdisInsight.
  6. ^ Bolger CA, Carpenter JE, Dhar TG, Pashine A, Dragovich PS, Cook JH, Gillis EP, Peese KM, Merritt JR. "Chapter 29: To Market, To Market--2017". 2018 Medicinal Chemistry Reviews. 53.
  7. ^ "Elpida (elsulfavirine) becomes the preferred first line therapy for treatment of HIV infection in Russia" (Press release). PRN Newswire. February 2, 2021.
  8. ^ Akram R, DeSimone Jr J (June 5, 201). "What's in the Pipeline?". Contagion. 4 (3).
  9. ^ Bichko V, Rogovoy B, Koryakova A (2017). "Pre-clinical pharmacokinetics of elsufavirine/VM1500A long acting injectable formulations". International Antiviral Society-USA. Poster WEPEA0190.
Stub icon

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Elsulfavirine&oldid=1204660734"